EMA starts review of Enhertu for HER2+ gastric cancerThe EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a Share XEMA starts review of Enhertu for HER2+ gastric cancerhttps://pharmaphorum.com/news/ema-starts-review-of-enhertu-for-her2-gastric-cancer/
European regulators back Blueprint’s Ayvakyt for stomach tumoursEuropean regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain Share XEuropean regulators back Blueprint’s Ayvakyt for stomach tumourshttps://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour – Share XBlueprint pays the price of Ayvakit phase 3 miss as FDA rejects drughttps://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/
Blueprint gets first approval as FDA backs stomach cancer drugUS biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for Share XBlueprint gets first approval as FDA backs stomach cancer drughttps://pharmaphorum.com/news/blueprint-gets-first-approval-as-fda-backs-stomach-cancer-drug/
Merck KGaA/Pfizer’s Bavencio fails in stomach cancer trialMerck KGaA and Pfizer’s cancer immunotherapy Bavencio has disappointed in a hard to treat late-stage gastric cancer trial, Share XMerck KGaA/Pfizer’s Bavencio fails in stomach cancer trialhttps://pharmaphorum.com/news/merck-kgaapfizers-bavencio-fails-stomach-cancer-trial/
